[Pharmacology of platinum compounds: differences between the three molecules and factors of interpatient variability].
Platinum compounds represent a pharmacological class, essential for the treatment of some cancer diseases. The three molecules, cisplatin, carboplatin, and oxaliplatin, share some physiochemical and pharmacological properties, in particular the ability to form DNA adducts. However, oxaliplatin presents some mechanisms of resistance different to those of cisplatin and carboplatin. Carboplatin may be considered as an analogue of cisplatin, but its pharmacokinetic properties, side effects, and intrinsic activity are significantly different from those of cisplatin, then the choice of one of these two compounds may be done rationally in function of the patients' characteristics. The cellular mechanisms involved in these differences are described in this general review.
Université de Toulouse, institut Claudius-Regaud, France. Chatelut.Etienne@claudiusregaud.fr
Etienne
E
Chatelut
D000970:Antineoplastic Agents / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D016190:Carboplatin / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D002945:Cisplatin / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D018736:DNA Adducts; D019008:Drug Resistance, Neoplasm; D006801:Humans; D006868:Hydrolysis; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009944:Organoplatinum Compounds / Q000737:chemistry / Q000493:pharmacokinetics / Q000494:pharmacology*; D000077150:Oxaliplatin; D057285:Precision Medicine; D012737:Sex Factors
D000970:Antineoplastic Agents; D018736:DNA Adducts; D009944:Organoplatinum Compounds; C096276:carboplatin-DNA adduct; C057270:cisplatin-DNA adduct; D000077150:Oxaliplatin; D016190:Carboplatin; D002945:Cisplatin